Bringing new medicines to women with epithelial ovarian cancer: what is the unmet medical need?

Table 1 Clinical activity of targeted therapies for treatment of recurrent ovarian cancer in heavily pretreated patients

	Phase	Patients with OC, n	Previous therapies	ORR, n (%)	CR, n (%)	Median DoR, mo	Median PFS, mo	OS, mo
Bevacizumab Monotherapy
Cannistra 2007 [21]	2	44	2–3	7 (16)	0	4.2	4.4	10.7
Burger 2007 [22]	2	62	1–2	13 (21)	2 (3)	10.3	4.7	16.9
Monk 2006 [23]		32	5 (range: 2–10)	5 (16)	1 (3)	NR	5.5	6.9
Pietzner 2011 [24]		15	5.4 (range: 1–7)	2 (13)	0	NR	NR	15.0
Bevacizumab-Chemotherapy Combination
AURELIA [25]	3	361	≤2	27.3%	NR	NR	6.7	16.6
OCEANS [26, 27]	2	484	≤1	190/242 (78.5)	42 (17)	10.4	12.4	33.6
GOG-213 [28]	3	674	≥3	196/249 (78)	79/249 (32)	NR	13.8	42.2
Olaparib Monotherapy
Kaufman 2015 [29]	2	193	4.3 ± 2.2 (SD)	60 (31)	6 (3)	7.5	7	16.6
≥ 3 Prior lines [30]^a		137^a	≥3	46 (34)	2 (2)	7.9	6.7	NR
Gelmon 2011 [31]	2	65	3 (range: 1–10)	18 (29)	0	NR	7.3	NR
Rucaparib Monotherapy
Swisher 2017 [32]	2
BRCA mutant		40	1–2	32 (80)	NR	9.2	12.8	NR
BRCA wild-type
LOH high		82	1–2	24 (29)	NR	10.8	5.7	NR
LOH low		70	1–2	7 (10)		5.6	5.2

CR complete response, DoR duration of response, LOH loss-of-heterozygosity score, mo months, NR not reported, OC ovarian cancer, ORR objective/overall response rate, OS overall survival, PFS progression-free survival, SD standard deviation
^aSubset of patients in Kaufman/Domchek who had measurable disease at baseline and ≥3 prior lines of chemotherapy

ISSN: 2053-6844